Bellicum Pharmaceuticals, Inc. BLCM and Astellas
Pharma Inc. ALPMY today announced that Agensys, Inc.
("Agensys"), an affiliate of Astellas, and Bellicum have entered into a
global license agreement, granting Bellicum rights to develop and
commercialize adoptive cell therapies, including CAR-T cells, for tumors
expressing Prostate Stem Cell Antigen (PSCA) using PSCA technology, both
in-licensed and developed at Agensys.
PSCA is a cancer antigen expressed in many malignancies, including
prostate, pancreatic, bladder, esophagus, and gastric cancers. Bellicum
is developing BPX-601, a GoCAR-T™ product candidate targeting PSCA that
has demonstrated robust anti-tumor activity in preclinical studies.
GoCAR-T is a proprietary Bellicum technology in which an MC (MyD88/CD40)
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in